Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 03-2016 | 12-2015 | 09-2015 | 06-2015 | 03-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 429 | 1,158 | 694 | 121 | 70 |
| TOTAL | $855 | $1,887 | $1,797 | $1,594 | $106 |
| Non-Current Assets | |||||
| PPE Net | 88 | 79 | 88 | 103 | 117 |
| Other Non-Current Assets | 47 | 47 | 47 | 47 | 47 |
| TOTAL | $135 | $126 | $135 | $150 | $164 |
| Total Assets | $990 | $2,012 | $1,933 | $1,744 | $270 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 8,304 |
| Accounts payable and accrued liabilities | 936 | 1,098 | 1,110 | 1,550 | 2,251 |
| Accrued Expenses | 814 | 929 | 1,131 | 1,382 | 1,207 |
| TOTAL | $1,795 | $2,102 | $2,349 | $3,279 | $17,388 |
| Non-Current Liabilities | |||||
| Long Term Debt | 27 | 29 | 31 | 1,039 | 36 |
| Other Non-Current Liabilities | 2,090 | 1,416 | 805 | 213 | 3,305 |
| TOTAL | $2,172 | $1,509 | $909 | $1,331 | $3,424 |
| Total Liabilities | $3,967 | $3,611 | $3,257 | $4,610 | $20,813 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 265 | 76 | 58 | 53 | 53 |
| Common Shares | 3 | 2 | 2 | 2 | 2 |
| Retained earnings | -131,743 | -123,242 | -121,095 | -114,047 | -84,523 |
| Other shareholders' equity | 32 | 32 | 32 | 32 | 32 |
| TOTAL | $-2,977 | $-1,598 | $-1,325 | $-2,866 | $-20,543 |
| Total Liabilities And Equity | $990 | $2,012 | $1,933 | $1,744 | $270 |